Souhaitez-vous accéder aux communiqués récents ?

Kneat announces record revenue for Q1 2026 of $18 million, up 18% from Q1 2025, and accelerating gross profit growth of 28% year-over-year.

DYADIC ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world...

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers - Phase 1 SAD and MAD data expected by year-end 2026 BEIJING,...

Responding to a press report, Kneat confirms its Board of Directors has formed a special committee to review strategic alternatives.

(OTCPK: MAJI) announce the commencement of the final stability phase for its inaugural line of commercial exosome products.

ICP-488 is expected to provide a novel therapeutic option for patients. There are no approved targeted therapies for Sjögren's syndrome globally.

The IND approval marks another milestone in our solid tumor pipeline and validates the huge drug development potential of our ADC platform.

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to...

2026 State of Validation study intensifying workload demands alongside advancements in digital validation and AI adoption.